United Kingdom (UK)
Recombinant monoclonal antibody to CD39. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma I-392.
UniProt Accession Number of Target Protein: P49961
Alternative Name(s) of Target: ENTPD1; NTPDase 1; Ectonucleoside triphosphate Di phosphohydrolase 1; Ecto-ATP Di phosphohydrolase 1; Ecto-ATPDase 1; Ecto-ATPase 1; Ecto-apyrase; Lymphoid cell activation antigen
Specificity: This antibody recognizes and binds human CD39. NTPDase 1 (ectonucleoside triphosphate diphosphohydrolase, also known as CD39/ENTPD1 or vascular CD39, functions together with another enzyme, CD73 (ecto-5'- nucleosidase), to hydrolyze extracellular adenosine triphosphate (ATP) and adenosine diphosphate (ADP) to generate adenosine, which binds to adenosine receptors and inhibits T-cell and natural killer (NK)-cell responses, thereby suppressing the immune system. This protein could also be implicated in the prevention of platelet aggregation by hydrolyzing platelet-activating ADP to AMP.
Application Notes: The binding characterization of this antibody for CD39 expressed on Ramos cells was done using flow cytometry (WO2018065552). The binding of this antibody to various recombinant human CD39 isoforms was detected using ELISA. This antibody bound only vascular CD39, without any binding to CD39-L1, CD39-L2, CD39-L3 or CD39-L4. This antibody did not induce or increase CD39 down regulation. It was reported that this antibody is very potent at blocking CD39 enzymatic activity and is capable of neutralizing ATPase activity (US20190153113).
Antibody first published in: PMID: